Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E14.04 EPS (ttm)7.25 Insider Own0.10% Shs Outstand706.70M Perf Week1.99%
Market Cap71.94B Forward P/E8.34 EPS next Y12.21 Insider Trans-1.58% Shs Float706.30M Perf Month3.17%
Income5.23B PEG0.95 EPS next Q2.69 Inst Own75.70% Short Float1.67% Perf Quarter12.86%
Sales16.35B P/S4.40 EPS this Y4.80% Inst Trans0.00% Short Ratio3.28 Perf Half Y8.58%
Book/sh14.22 P/B7.16 EPS next Y12.67% ROA14.40% Target Price97.60 Perf Year20.79%
Cash/sh13.19 P/C7.72 EPS next 5Y14.70% ROE72.10% 52W Range58.59 - 101.22 Perf YTD58.84%
Dividend- P/FCF9.44 EPS past 5Y26.50% ROI16.50% 52W High0.57% Beta1.39
Dividend %- Quick Ratio3.30 Sales past 5Y18.70% Gross Margin96.20% 52W Low73.75% ATR0.99
Employees8852 Current Ratio3.40 Sales Q/Q15.40% Oper. Margin44.70% RSI (14)69.75 Volatility0.81% 1.01%
OptionableYes Debt/Eq1.97 EPS Q/Q51.60% Profit Margin32.20% Rel Volume0.93 Prev Close100.97
ShortableYes LT Debt/Eq1.97 EarningsOct 24 BMO Payout0.00% Avg Volume3.58M Price101.80
Recom2.90 SMA202.43% SMA504.38% SMA2009.49% Volume3,339,959 Change0.82%
Aug-19-19Downgrade Mizuho Buy → Neutral $103 → $100
May-03-19Downgrade Barclays Overweight → Equal Weight $102
Apr-01-19Downgrade William Blair Outperform → Mkt Perform
Apr-01-19Downgrade UBS Buy → Neutral $94 → $102
Apr-01-19Downgrade Atlantic Equities Overweight → Neutral
Feb-01-19Downgrade Jefferies Buy → Hold $95
Jan-04-19Upgrade Robert W. Baird Neutral → Outperform
Jan-04-19Upgrade Goldman Sell → Neutral
Dec-21-18Resumed BTIG Research Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $100
Jun-18-18Upgrade Standpoint Research Hold → Buy
May-29-18Reiterated SunTrust Hold $106 → $96
May-23-18Upgrade Bernstein Mkt Perform → Outperform
May-23-18Downgrade Argus Buy → Hold
May-07-18Downgrade RBC Capital Mkts Top Pick → Outperform
Apr-13-18Resumed Morgan Stanley Equal-Weight $93
Mar-26-18Reiterated Goldman Sell $97 → $85
Mar-21-18Resumed JP Morgan Overweight $110
Feb-28-18Reiterated Stifel Buy $130 → $128
Feb-28-18Downgrade SunTrust Buy → Hold
Oct-17-19 11:24AM  Lilly's Pancreatic Cancer Candidate Fails in Phase III Study Zacks
10:41AM  4 Biotech Stocks That Are Set to Rally, Analyst Says
10:33AM  Celgene (CELG) Earnings Expected to Grow: Should You Buy? Zacks
Oct-16-19 12:16PM  Editas Inks Deal for Gene Editing Neurological Disease Drugs Zacks
06:00AM  Celgene and the Multiple Sclerosis Association of America Take the MS MindShift Initiative and Brain Bulb Hot Air Balloon to the Sky at Owl-O-Ween Festival to Educate on Multiple Sclerosis and Brain Health Business Wire
Oct-15-19 12:21PM  AbbVie, Bristol-Myers Squibb Getting the Most From Workers
Oct-11-19 09:45AM  Geron Starts Enrollment in Phase III MDS Study on Imetelstat Zacks
Oct-10-19 04:08PM  6 Stocks Trading Below Peter Lynch Value
Oct-08-19 09:18AM  Why Alexion is a Hot Takeover Target in the Biotech Sector Zacks
Oct-04-19 09:30AM  3 Drug Stocks Poised for Gains After Cancer Conference Investopedia
08:00AM  Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It? Investor's Business Daily
Oct-03-19 04:49PM  Here is Hedge Funds 17th Most Popular Stock Pick Insider Monkey
03:02PM  3 Cancer-Fighting Drug Stocks to Buy Right Now InvestorPlace
10:00AM  BMY Stock Plus Celgene Will Be A Top 5 Pharma But Should You Buy It? Investor's Business Daily
Oct-02-19 11:36AM  Agios' Tibsovo Improves Survival in Cholangiocarcinoma Study Zacks
Oct-01-19 10:36AM  Geron's Imetelstat Gets Fast Track Status for Myelofibrosis Zacks
08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Sep-30-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
Sep-27-19 10:47AM  Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance Zacks
Sep-25-19 10:36AM  Adding Biotech ETFs to Your Portfolio Investopedia
Sep-23-19 05:50PM  Celgene (CELG) Gains As Market Dips: What You Should Know Zacks
Sep-20-19 05:48PM  3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices
11:04AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
08:31AM  3 Big Biotech Stocks Worth Adding to Your Portfolio Now Zacks
07:30AM  Celgene Corporation Names Second Round of Celgene Cancer Care Links Program Grant Recipients Business Wire
Sep-18-19 10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
10:33AM  Acceleron Discontinues Mid-Stage Muscular Dystrophy Study Zacks
Sep-17-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
10:39AM  Karyopharm Signs $150M Royalty Agreement to Support Xpovio Zacks
10:14AM  The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial Zacks
Sep-16-19 02:25PM  Top Stock Reports for Celgene, Sinopec & HSBC Zacks
08:48AM  Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study Zacks
Sep-13-19 10:30AM  Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks
09:18AM  Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says
07:40AM  The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans Benzinga
Sep-12-19 04:30PM  Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints Business Wire
09:41AM  J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients Zacks
Sep-11-19 05:50PM  Celgene (CELG) Outpaces Stock Market Gains: What You Should Know Zacks
Sep-10-19 06:00PM  FDA Grants Orphan Drug Status to Acceleron's PAH Candidate Zacks
Sep-09-19 07:30AM  Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Business Wire
Sep-08-19 09:00AM  Better Buy: Amgen vs. Celgene Motley Fool
Sep-07-19 12:30PM  Is Bristol-Myers Squibb a Buy? Motley Fool
Sep-06-19 03:06PM  Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool
08:39AM  Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer Zacks
05:21AM  China biotech group shares slide over accusation of sales inflation Financial Times
Sep-05-19 05:50PM  Celgene (CELG) Gains But Lags Market: What You Should Know Zacks
04:51PM  3 Special Situations Gurus Are Buying
Sep-04-19 09:39AM  Roche Extends Offer to Acquire Spark Therapeutics Yet Again Zacks
Sep-03-19 05:46PM  Top-Performing Biotech ETFs YTD Zacks
07:02AM  5 Cancer-Fighting Stocks to Add to Your Portfolio Zacks
06:30AM  The 3 Best Health Care Stocks So Far This Year
Aug-30-19 05:45PM  Celgene (CELG) Stock Sinks As Market Gains: What You Should Know Zacks
Aug-29-19 11:24AM  Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer Zacks
10:18AM  Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why Zacks
09:31AM  Why Is Celgene (CELG) Up 6.1% Since Last Earnings Report? Zacks
Aug-28-19 06:55PM  What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals Zacks
01:56PM  Bristol-Myers Squibb Gains Europe's Approval for Empliciti
10:54AM  Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To $1.59B Benzinga
10:38AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health Zacks
10:34AM  Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More Zacks
10:15AM  Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion Zacks
06:28AM  Alexion Wins EC Nod for Soliris in Nervous System Disorder Zacks
Aug-27-19 11:01AM  4 Biotech Stocks to Buy That Are on the Move InvestorPlace
10:55AM  Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy? Zacks
10:18AM  Amgen Paid Too Much for Otezla. Why One Analyst Says It Was the Right Thing to Do.
10:07AM  Company News for Aug 27, 2019 Zacks
10:05AM  Amgen to Buy Celgene's Otezla: 5 ETF Drugs Zacks
09:24AM  3 Cancer Treatment Stocks to Enrich Your Portfolio Zacks
08:58AM  Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene Zacks
08:05AM  Bristol-Myers Announces Sale of Celgene's Otezla to Amgen Zacks
12:00AM  Amgen adds Otezla to its medicine cabinet Financial Times
Aug-26-19 10:04PM  US Stock Market Overview – Stock Surge as Trump Flip Flops Lifting Dow Industrials FX Empire
05:06PM  What Happened in the Stock Market Today Motley Fool
04:34PM  Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks InvestorPlace
04:32PM  Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win Motley Fool
04:18PM  US STOCKS-Wall Street bounces as trade temperature cools Reuters
04:15PM  Why Amgen's $13.4 Billion Otezla Buy Is A Boon For These Biotechs Investor's Business Daily
04:00PM  Wall Street Rebounds Monday
03:32PM  5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY InvestorPlace
01:53PM  Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen InvestorPlace
01:21PM  Amgen's Proposed $13.4B Acquisition Of Celgene's Otezla: What You Need To Know Benzinga
12:53PM  Amgen stock pops after company agrees to buy Celgenes blockbuster anti-inflammatory drug Otezla MarketWatch
12:52PM  The Dow Is Up Because Markets Want to Believe the Trade War Can End
12:50PM  Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela
10:57AM  Amgen Will Buy Celgene Drug in $13.4 Billion Antitrust Sale Bloomberg
09:59AM  Dow Jones Today: Apple, Boeing Lead; Celgene Surges On Amgen Deal Investor's Business Daily
09:14AM  Bristol-Meyers Deal for Celgene Moves Ahead After the Sale of Psoriasis Drug
08:17AM  Otezla Price Under Microscope -- but Look Closely and It Checks Out
08:16AM  Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion Reuters
08:02AM  Alexion Shares Decline in Wake of Amgen's Deal for Otezla
07:50AM  Amgen to buy Celgenes Otezla in $13.4bn deal Financial Times
06:50AM  Amgen to buy Celgene's Otezla for $13.4 billion MarketWatch
06:46AM  Celgene to sell psoriasis drug Otezla for $13.4 billion to Amgen Reuters
06:30AM  Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits PR Newswire
05:53AM  Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term
05:28AM  [video]Put the Pajamas Away: Jim Cramer on U.S.-China Trade and Amgen
04:49AM  Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation
03:29AM  Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash
Aug-25-19 05:00PM  3 Cancer Treatment Stocks to Buy Right Now Motley Fool
02:00PM  Better Buy: Biogen vs. Celgene Motley Fool
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curran TerrieSEE REMARKSSep 18Option Exercise58.334,500262,48513,493Sep 19 04:05 PM
Curran TerrieSEE REMARKSSep 18Sale98.2711,3381,114,1442,155Sep 19 04:05 PM
Elkins David VEVP, CHIEF FINANCIAL OFFICERAug 01Option Exercise0.0024,947024,947Aug 05 04:00 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.0037502,209Jun 17 04:00 PM
BARKER RICHARD WDirectorJun 15Option Exercise0.001,125013,673Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.002,441041,861Jun 17 04:00 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375062,884Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 17 04:00 PM
Haller Julia ADirectorJun 15Option Exercise0.0037502,409Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0030001,834Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 14Option Exercise0.00300039,420Jun 17 04:00 PM
Friedman Michael ADirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
MARIO ERNESTDirectorJun 14Option Exercise0.00300062,509Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 14Option Exercise0.0030000Jun 17 04:00 PM
Haller Julia ADirectorJun 14Option Exercise0.0030002,034Jun 17 04:00 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0048401,534Jun 17 04:00 PM
LOUGHLIN JAMES JDirectorJun 13Option Exercise0.00484039,120Jun 17 04:00 PM
Friedman Michael ADirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
MARIO ERNESTDirectorJun 13Option Exercise0.00484062,209Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 13Option Exercise0.0048400Jun 17 04:00 PM
Haller Julia ADirectorJun 13Option Exercise0.0048401,734Jun 17 04:00 PM
CASEY MICHAEL DDirectorJun 03Option Exercise22.4724,666554,24524,666Jun 05 04:05 PM
Curran TerrieSEE REMARKSMay 02Option Exercise0.001,56309,483May 06 04:05 PM
VESSEY RUPERTSEE REMARKSMay 02Option Exercise0.006,731013,984May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMay 02Option Exercise0.0015,6080227,886May 06 04:05 PM
Biller JonathanEVP AND GENERAL COUNSELMay 02Option Exercise0.001,56304,674May 06 04:05 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYMay 02Option Exercise0.001,563013,124May 06 04:05 PM
Alles Mark JCEO, CHAIRMAN OF BOARDMar 01Option Exercise0.0033,8090226,178Mar 05 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Option Exercise22.4724,666554,24562,102Feb 11 04:05 PM
LOUGHLIN JAMES JDirectorFeb 07Sale87.2923,4662,048,32438,636Feb 11 04:05 PM
MARIO ERNESTDirectorDec 19Option Exercise59.068,600507,87363,013Dec 20 04:48 PM
Biller JonathanEVP AND GENERAL COUNSELDec 16Option Exercise0.001,90004,046Dec 18 06:45 PM
VESSEY RUPERTSEE REMARKSDec 16Option Exercise0.005,35009,887Dec 18 06:43 PM
Curran TerrieSEE REMARKSDec 16Option Exercise0.002,50009,151Dec 18 06:28 PM
AHMED NADIMPRES., HEMATOLOGY AND ONCOLOGYDec 16Option Exercise0.003,000013,038Dec 18 06:26 PM
Alles Mark JCEO, CHAIRMAN OF BOARDDec 16Option Exercise0.008,9290196,245Dec 18 06:25 PM
MARIO ERNESTDirectorNov 26Option Exercise59.0610,000590,55054,413Nov 28 04:05 PM